Security
Evommune, Inc. · EVMN
EVMNNYSECommon stockCurrentCIK 2044725Updated Nov 11, 2026
EVMN price & chart
Loading TradingView…
NYSE:EVMN on TradingView ↗About the company
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
In the news
NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading USA - English APAC - English News provided by New York Stock Exchange Nov 06, 2025, 08:55 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 6, 2025 /PRNewswire/ -- The New York Stock Exchange ↗
Recent filings
SCHEDULE 13D/A filing
Regulation FD Disclosure
Items 7.01, 9.01
424B3 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure · Other Events
Items 1.01, 3.02, 7.01, 8.01
4 filing
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
424B3 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| AssetsUSD | 84,544,000Source | — | 301,947,000Source | — | 322,455,000Source | — | 224,946,000Source | 76,055,000Source |
| Property, Plant and Equipment, NetUSD | 970,000Source | — | 1,650,000Source | — | 1,640,000Source | — | 994,000Source | 1,326,000Source |
| Current assets: | ||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 26,818,000Source | 18,146,000Source | 60,034,000Source | 61,837,000Source | 48,318,000Source | 5,704,000Source | 44,063,000Source | 16,255,000Source |
| Assets, CurrentUSD | 81,941,000Source | — | 204,246,000Source | — | 215,855,000Source | — | 153,478,000Source | 73,988,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,879,000Source | — | 3,453,000Source | — | 4,391,000Source | — | 4,278,000Source | 1,948,000Source |
| Operating Lease, Right-of-Use AssetUSD | 160,000Source | — | 7,568,000Source | — | 7,930,000Source | — | 1,469,000Source | 472,000Source |
| Other Assets, NoncurrentUSD | 61,000Source | — | 66,000Source | — | 73,000Source | — | 101,000Source | 61,000Source |
| LIABILITIES AND EQUITY | ||||||||
| LiabilitiesUSD | 10,677,000Source | — | 24,361,000Source | — | 17,900,000Source | — | 19,380,000Source | 28,516,000Source |
| Stockholders’ equity: | ||||||||
| Common Stock, Value, IssuedUSD | 0Source | — | 4,000Source | — | 4,000Source | — | 3,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -192,816,000Source | — | -275,009,000Source | — | -242,763,000Source | — | -221,089,000Source | -152,219,000Source |
| Stockholders' Equity Attributable to ParentUSD | -183,137,000Source | -122,528,000Source | 277,586,000Source | -171,233,000Source | 304,555,000Source | -158,239,000Source | 205,566,000Source | -144,237,000Source |
| Additional Paid in Capital, Common StockUSD | 9,679,000Source | — | 552,591,000Source | — | 547,314,000Source | — | 426,652,000Source | 7,982,000Source |
| Liabilities and EquityUSD | 84,544,000Source | — | 301,947,000Source | — | 322,455,000Source | — | 224,946,000Source | 76,055,000Source |
| Current liabilities: | ||||||||
| Liabilities, CurrentUSD | 10,416,000Source | — | 17,487,000Source | — | 10,603,000Source | — | 17,909,000Source | 27,981,000Source |
| Operating Lease, Liability, CurrentUSD | 160,000Source | — | 1,237,000Source | — | 1,253,000Source | — | 242,000Source | 487,000Source |
| Accounts Payable, CurrentUSD | 3,576,000Source | — | 5,044,000Source | — | 4,045,000Source | — | 7,756,000Source | 8,264,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | — | 6,440,000Source | — | 6,768,000Source | — | 1,290,000Source | — |
| Additional Financial Items | ||||||||
| Accrued Liabilities, CurrentUSD | 6,309,000Source | — | 10,688,000Source | — | 4,734,000Source | — | 9,547,000Source | 6,729,000Source |
| Short-term InvestmentsUSD | 49,244,000Source | — | 140,759,000Source | — | 163,146,000Source | — | 105,137,000Source | 55,785,000Source |
| Other Liabilities, Noncurrent | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -21,674,000Source | -14,557,000Source | -68,870,000Source | -66,808,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | 200,000Source | 200,000Source | 100,000Source | 200,000Source | 600,000Source | 500,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,454,000Source | 544,000Source | 5,856,000Source | 1,722,000Source |
| Changes in operating assets and liabilities: | ||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -3,749,000Source | -691,000Source | -837,000Source | 6,506,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -27,503,000Source | -23,899,000Source | -76,441,000Source | -58,195,000Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -85,359,000Source | 13,500,000Source | -115,307,000Source | -3,993,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 83,000Source | 0Source | 235,000Source | 88,000Source |
| Cash flows from financing activities: | ||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 1,224,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 117,111,000Source | -152,000Source | 220,763,000Source | 49,419,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 4,249,000Source | -10,551,000Source | 29,015,000Source | -12,769,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 28,230,000Source | 18,354,000Source | 61,237,000Source | 62,045,000Source | 49,727,000Source | 5,912,000Source | 45,478,000Source | 16,463,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 4,000Source | 4,000Source | 7,000Source | 34,000Source |
| Additional Financial Items | ||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 561,000Source | 401,000Source | 4,598,000Source | 557,000Source | 3,454,000Source | 544,000Source | 5,856,000Source | 1,722,000Source |
| General and Administrative ExpenseUSD | — | — | 3,689,000Source | 3,228,000Source | 8,483,000Source | 3,356,000Source | 6,635,000Source | 3,670,000Source | 20,029,000Source | 12,769,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 862,000Source | 618,000Source | 2,651,000Source | 403,000Source | 2,284,000Source | 613,000Source | 3,323,000Source | 3,242,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,475,000Source | -15,916,000Source | -32,246,000Source | -13,565,000Source | -21,674,000Source | -14,557,000Source | -68,870,000Source | -66,808,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -12,475,000Source | -15,916,000Source | — | — | — | — | -68,870,000Source | -68,308,000Source |
| Operating ExpensesUSD | — | — | 23,328,000Source | 16,517,000Source | 34,895,000Source | 22,994,000Source | 23,954,000Source | 18,032,000Source | 94,071,000Source | 77,013,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 853,000Source | 601,000Source | 2,649,000Source | 9,429,000Source | 2,280,000Source | 475,000Source | 12,201,000Source | 3,205,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 108,776,000Source | 0Source | 199,172,000Source | 90,255,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 2,000Source | 6,000Source | 13,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | 0Source | 0Source | 0Source | 3,000,000Source | 13,000,000Source | 7,000,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | — | — | — | —Source | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 10,000,000Source | — | 0Source | 0Source | 0Source | 3,000,000Source | 13,000,000Source | 7,000,000Source |
| Operating Income (Loss)USD | — | — | -13,328,000Source | -16,517,000Source | -34,895,000Source | -22,994,000Source | -23,954,000Source | -15,032,000Source | -81,071,000Source | -70,013,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 853,000Source | 601,000Source | 2,649,000Source | 9,429,000Source | 2,280,000Source | 475,000Source | 12,201,000Source | 3,205,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -68,870,000Source | -68,308,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,475,000Source | -15,916,000Source | -32,246,000Source | -13,565,000Source | -21,674,000Source | -14,557,000Source | -68,870,000Source | -66,808,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -8.07Source | -10.47Source | -0.89Source | -8.8Source | -0.64Source | -9.48Source | -11.22Source | -45.29Source |
| Earnings Per Share, DilutedUSD per share | — | — | -8.07Source | -10.47Source | -0.89Source | -8.8Source | -0.64Source | -9.48Source | -11.22Source | -45.29Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,545,010Source | 1,520,814Source | 36,135,644Source | 1,540,695Source | 33,670,148Source | 1,534,965Source | 6,136,636Source | 1,508,284Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,545,010Source | 1,520,814Source | 36,135,644Source | 1,540,695Source | 33,670,148Source | 1,534,965Source | 6,136,636Source | 1,508,284Source |
| Additional Financial Items | ||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 349,000Source | 377,000Source | 1,389,000Source | 1,287,000Source |
| General and Administrative ExpenseUSD | — | — | 3,689,000Source | 3,228,000Source | 8,483,000Source | 3,356,000Source | 6,635,000Source | 3,670,000Source | 20,029,000Source | 12,769,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -68,870,000Source | -68,308,000Source |
| Investment Income, InterestUSD | — | — | 862,000Source | 618,000Source | 2,651,000Source | 403,000Source | 2,284,000Source | 613,000Source | 3,323,000Source | 3,242,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -12,475,000Source | -15,916,000Source | — | — | — | — | -68,870,000Source | -68,308,000Source |
| Operating ExpensesUSD | — | — | 23,328,000Source | 16,517,000Source | 34,895,000Source | 22,994,000Source | 23,954,000Source | 18,032,000Source | 94,071,000Source | 77,013,000Source |
| Research and Development ExpenseUSD | — | — | 19,639,000Source | 13,289,000Source | 26,412,000Source | 19,638,000Source | 17,319,000Source | 14,362,000Source | 74,042,000Source | 64,244,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | 0Source | 0Source | 0Source | 3,000,000Source | 13,000,000Source | 7,000,000Source |
Offerings
Registration 333-295140
Registration 333-290793
- Gross proceeds
- 150000000.0
- Net proceeds
- 139500000.0
- Deal price
- 16.0
- Shares
- 9375000
- Offering price
- $16.00
- Ticker
- EVMN
Filing attachments
evmn-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Evommune to Host Webcast on EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader PALO ALTO, Calif., NEW YORK, November 5, 2026 - Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be avai…
Read attachment ↗evmn-ex4_1.htm · 8-K · 2026-11-04
Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED, OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STA…
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-11-04
Exhibit 99.1 Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals - Oral, highly selective and potent VAV1 molecular glue degrader designed to deliver a differentiated clinical profile across a broad range of indications in autoimmune disease - Phase 1 expected to begin imminently; Evommune plans to initiate a Phase 2 trial in rheumatoid arthritis in 2027 - Evommune to pay $20MM upfront in cash and $10MM…
Read attachment ↗evmn-ex99_2.htm · 8-K · 2026-11-04
Exhibit 99.2 Evommune Announces $30 Million Private Placement Palo Alto, CA., and New York, NY., November 4, 2026 - Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare institutional investors in a priva…
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-10-01
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL‑18 inhibition as a novel, clinically relevant approach to treating atopic dermatitis - Biomarker analyses confirm robust Th2 pathway modulation, as well as broad anti‑inflammatory activity across multiple inflammat…
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-09-23
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Palo Alto, Calif., and New York, September 23, 2026 - Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis …
Read attachment ↗